SK181498A3 - Method for producing therapeutic dna, application of plasmid dna for producing a pharmaceutical composition - Google Patents

Method for producing therapeutic dna, application of plasmid dna for producing a pharmaceutical composition Download PDF

Info

Publication number: SK181498A3
Authority: SK; Slovakia
Prior art keywords: dna; plasmid; methylated; dinucleotides; plasmid dna
Prior art date: 1996-07-04

Application number

SK1814-98A

Other languages

English (en)

Slovak (sk)

Inventor

Joel Crouzet

Beatrice Cameron

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-04

Filing date

1997-06-24

Publication date

1999-07-12

1997-06-24 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1999-07-12 Publication of SK181498A3 publication Critical patent/SK181498A3/sk

Links

239000013612 plasmid Substances 0.000 title claims abstract description 153
230000001225 therapeutic effect Effects 0.000 title claims description 20
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
238000004519 manufacturing process Methods 0.000 title abstract description 7
238000002360 preparation method Methods 0.000 claims abstract description 26
108020004414 DNA Proteins 0.000 claims description 142
210000004027 cell Anatomy 0.000 claims description 59
238000000034 method Methods 0.000 claims description 50
230000014509 gene expression Effects 0.000 claims description 45
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 36
239000013598 vector Substances 0.000 claims description 33
108020004707 nucleic acids Proteins 0.000 claims description 19
102000039446 nucleic acids Human genes 0.000 claims description 19
150000007523 nucleic acids Chemical class 0.000 claims description 19
108060004795 Methyltransferase Proteins 0.000 claims description 18
102000016397 Methyltransferase Human genes 0.000 claims description 18
108010063593 DNA modification methylase SssI Proteins 0.000 claims description 9
102000055027 Protein Methyltransferases Human genes 0.000 claims description 9
241000894006 Bacteria Species 0.000 claims description 8
108020000946 Bacterial DNA Proteins 0.000 claims description 8
108700040121 Protein Methyltransferases Proteins 0.000 claims description 8
230000003362 replicative effect Effects 0.000 claims description 8
230000001939 inductive effect Effects 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 4
210000001236 prokaryotic cell Anatomy 0.000 claims description 2
108020004638 Circular DNA Proteins 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000001415 gene therapy Methods 0.000 abstract description 16
230000001580 bacterial effect Effects 0.000 abstract description 7
108090000623 proteins and genes Proteins 0.000 description 65
230000011987 methylation Effects 0.000 description 20
238000007069 methylation reaction Methods 0.000 description 20
241000588724 Escherichia coli Species 0.000 description 19
102000004190 Enzymes Human genes 0.000 description 17
108090000790 Enzymes Proteins 0.000 description 17
230000010076 replication Effects 0.000 description 14
238000001890 transfection Methods 0.000 description 11
239000000243 solution Substances 0.000 description 10
230000002163 immunogen Effects 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
238000000338 in vitro Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
238000012546 transfer Methods 0.000 description 7
108700039691 Genetic Promoter Regions Proteins 0.000 description 6
239000002253 acid Substances 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
229930027917 kanamycin Natural products 0.000 description 6
229960000318 kanamycin Drugs 0.000 description 6
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
229930182823 kanamycin A Natural products 0.000 description 6
230000007017 scission Effects 0.000 description 6
-1 ApoAIV Proteins 0.000 description 5
102000053602 DNA Human genes 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000003550 marker Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
108010074328 Interferon-gamma Proteins 0.000 description 4
229930183998 Lividomycin Natural products 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
230000029087 digestion Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000028993 immune response Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229950003076 lividomycin Drugs 0.000 description 4
DBLVDAUGBTYDFR-SWMBIRFSSA-N lividomycin A Chemical compound O([C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@H]([C@H]1O)O[C@H]1O[C@H]([C@H]([C@H](O)[C@H]1N)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)CN)[C@H]1O[C@H](CO)[C@@H](O)C[C@H]1N DBLVDAUGBTYDFR-SWMBIRFSSA-N 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000009466 transformation Effects 0.000 description 4
229960005486 vaccine Drugs 0.000 description 4
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 3
230000007067 DNA methylation Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
241000202911 Spiroplasma sp. Species 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000047 product Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
241000589155 Agrobacterium tumefaciens Species 0.000 description 2
235000014469 Bacillus subtilis Nutrition 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000193403 Clostridium Species 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
241000194031 Enterococcus faecium Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
101000622060 Photinus pyralis Luciferin 4-monooxygenase Proteins 0.000 description 2
241000589776 Pseudomonas putida Species 0.000 description 2
108020005091 Replication Origin Proteins 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
241000589180 Rhizobium Species 0.000 description 2
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 2
241000202917 Spiroplasma Species 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
241000187747 Streptomyces Species 0.000 description 2
241001518258 Streptomyces pristinaespiralis Species 0.000 description 2
108700005078 Synthetic Genes Proteins 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
238000001261 affinity purification Methods 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
108020004084 membrane receptors Proteins 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
244000005700 microbiome Species 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
150000008300 phosphoramidites Chemical class 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
102100022464 5'-nucleotidase Human genes 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
101100381862 Bacillus subtilis (strain 168) bmr3 gene Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
101150102464 Cry1 gene Proteins 0.000 description 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
102100036912 Desmin Human genes 0.000 description 1
108010044052 Desmin Proteins 0.000 description 1
102000001039 Dystrophin Human genes 0.000 description 1
108010069091 Dystrophin Proteins 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
102000030914 Fatty Acid-Binding Human genes 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
108091092584 GDNA Proteins 0.000 description 1
101150057182 GFAP gene Proteins 0.000 description 1
102000004038 Glia Maturation Factor Human genes 0.000 description 1
108090000495 Glia Maturation Factor Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
241000588915 Klebsiella aerogenes Species 0.000 description 1
241000588747 Klebsiella pneumoniae Species 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100012330 Mus musculus F9 gene Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000008763 Neurofilament Proteins Human genes 0.000 description 1
108010088373 Neurofilament Proteins Proteins 0.000 description 1
108090000742 Neurotrophin 3 Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
101150038013 PIR gene Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241000588701 Pectobacterium carotovorum Species 0.000 description 1
102100035194 Placenta growth factor Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
102000018120 Recombinases Human genes 0.000 description 1
108010091086 Recombinases Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
102100032889 Sortilin Human genes 0.000 description 1
101100344811 Starmerella bombicola mdr gene Proteins 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
102100038313 Transcription factor E2-alpha Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
241001672648 Vieira Species 0.000 description 1
102000013127 Vimentin Human genes 0.000 description 1
108010065472 Vimentin Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
210000001766 X chromosome Anatomy 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
244000309466 calf Species 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
239000005516 coenzyme A Substances 0.000 description 1
229940093530 coenzyme a Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
210000005045 desmin Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
101150097231 eg gene Proteins 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940092559 enterobacter aerogenes Drugs 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
108091022862 fatty acid binding Proteins 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000006607 hypermethylation Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
101150023497 mcrA gene Proteins 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
230000001035 methylating effect Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
102000003702 retinoic acid receptors Human genes 0.000 description 1
108090000064 retinoic acid receptors Proteins 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
108020003113 steroid hormone receptors Proteins 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
239000012536 storage buffer Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
101150107585 tetA gene Proteins 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000012991 uterine carcinoma Diseases 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
108090000195 villin Proteins 0.000 description 1
210000005048 vimentin Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Crystallography & Structural Chemistry (AREA)
Analytical Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK1814-98A 1996-07-04 1997-06-24 Method for producing therapeutic dna, application of plasmid dna for producing a pharmaceutical composition SK181498A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9608327A FR2750704B1 (fr)	1996-07-04	1996-07-04	Procede de production d'adn therapeutique
PCT/FR1997/001116 WO1998001540A1 (fr)	1996-07-04	1997-06-24	Procede de production d'adn therapeutique

Publications (1)

Publication Number	Publication Date
SK181498A3 true SK181498A3 (en)	1999-07-12

Family

ID=9493705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1814-98A SK181498A3 (en)	1996-07-04	1997-06-24	Method for producing therapeutic dna, application of plasmid dna for producing a pharmaceutical composition

Country Status (14)

Country	Link
US (2)	US6410273B1 (fr)
EP (1)	EP0914418A1 (fr)
JP (1)	JP2000514293A (fr)
KR (1)	KR20000022488A (fr)
AU (1)	AU722909B2 (fr)
BR (1)	BR9710173A (fr)
CA (1)	CA2258792A1 (fr)
CZ (1)	CZ438298A3 (fr)
FR (1)	FR2750704B1 (fr)
IL (1)	IL127620A0 (fr)
NO (1)	NO986177L (fr)
SK (1)	SK181498A3 (fr)
WO (1)	WO1998001540A1 (fr)
ZA (1)	ZA975959B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7026468B2 (en)	1996-07-19	2006-04-11	Valentis, Inc.	Process and equipment for plasmid purification
US7807822B2 (en)	1996-08-01	2010-10-05	Robert Bridenbaugh	Methods for purifying nucleic acids
US7026155B2 (en) *	1999-02-02	2006-04-11	Regents Of The University Of California	Method of reducing bacterial proliferation
AU2001290984A1 (en) *	2000-09-18	2002-04-02	Genzyme Corporation	Expression vectors containing hybrid ubiquitin promoters
GB0025913D0 (en) *	2000-10-23	2000-12-06	Guldberg Per	Materials and methods relating to nucleic acid amplification and profiling
US20030152950A1 (en) *	2001-06-27	2003-08-14	Garner Harold R.	Identification of chemically modified polymers
US8765408B2 (en)	2002-01-23	2014-07-01	Wisconsin Alumni Research Foundation	Prophage element-free bacteria
US6989265B2 (en) *	2002-01-23	2006-01-24	Wisconsin Alumni Research Foundation	Bacteria with reduced genome
US8119365B2 (en) *	2002-01-23	2012-02-21	Wisconsin Alumni Research Foundation	Insertion sequence-free bacteria
US8039243B2 (en) *	2002-01-23	2011-10-18	Wisconsin Alumni Research Foundation	Insertion sequence-free bacteria
US20060270043A1 (en) *	2002-01-23	2006-11-30	Blattner Frederick R	Bacteria with reduced genome
US7303906B2 (en)	2002-09-06	2007-12-04	Wisconsin Alumni Research Foundation	Competent bacteria
US20090191218A1 (en)	2005-05-11	2009-07-30	Fengchun Li	DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
DE602006015373D1 (de) *	2005-05-11	2010-08-19	Univ Loma Linda	Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
CA2663026C (fr) *	2006-09-28	2013-04-16	Loma Linda University	Transfection apoptotique a mediation cellulaire de cellules de mammifere par arn interferant
GB0701253D0 (en)	2007-01-23	2007-02-28	Diagnostics For The Real World	Nucleic acid amplification and testing
EP3760226A1 (fr)	2011-09-23	2021-01-06	Loma Linda University	Souches bactériennes exprimant des gènes de méthylase et leurs utilisations
US11680273B2 (en)	2011-09-23	2023-06-20	Loma Linda University	Treatment of autoimmune diseases
EP3921416A1 (fr) *	2019-02-06	2021-12-15	Fred Hutchinson Cancer Research Center	Bactéries productrices de minicercle conçues pour produire de manière différentielle des molécules d'acide nucléique à l'intérieur de celles-ci

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5693622A (en)	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5491060A (en) *	1989-05-01	1996-02-13	The University Of Maryland	Mutant strain of E. coli for detection of methyltransferase clones
EP0412676B1 (fr) *	1989-08-07	1995-06-07	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Procédé de production de la DNA méthylase de spiroplasma sp.
US5405760A (en) *	1992-04-30	1995-04-11	New England Biolabs, Inc.	Process for producing recombinant McrBC endonuclease and cleavage of methylated DNA
US5470740A (en) *	1993-11-04	1995-11-28	Life Technologies, Inc.	Cloned NsiI restriction-modification system
US5587305A (en) *	1993-12-06	1996-12-24	The United States Of America As Represented By The Department Of Agriculture	Pasteurella haemolytica transformants
FR2714830B1 (fr)	1994-01-10	1996-03-22	Rhone Poulenc Rorer Sa	Composition contenant des acides nucléiques, préparation et utilisations.
CA2560114A1 (fr) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Oligonucleotides immunomodulateurs
FR2730637B1 (fr)	1995-02-17	1997-03-28	Rhone Poulenc Rorer Sa	Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
FR2739292B1 (fr)	1995-09-28	1997-10-31	Rhone Poulenc Rorer Sa	Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
FR2741066B1 (fr)	1995-11-14	1997-12-12	Rhone Poulenc Rorer Sa	Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2754272B1 (fr)	1996-10-08	1998-11-13	Rhone Poulenc Rorer Sa	Procede de preparation de compositions pour le transfert d'acides nucleiques
US6060245A (en)	1996-12-13	2000-05-09	Stratagene	Methods and adaptors for generating specific nucleic acid populations

1996
- 1996-07-04 FR FR9608327A patent/FR2750704B1/fr not_active Expired - Fee Related
1997
- 1997-06-24 JP JP10504844A patent/JP2000514293A/ja active Pending
- 1997-06-24 AU AU34475/97A patent/AU722909B2/en not_active Ceased
- 1997-06-24 BR BR9710173A patent/BR9710173A/pt not_active Application Discontinuation
- 1997-06-24 EP EP97930569A patent/EP0914418A1/fr not_active Withdrawn
- 1997-06-24 KR KR1019980710929A patent/KR20000022488A/ko not_active Ceased
- 1997-06-24 CA CA002258792A patent/CA2258792A1/fr not_active Abandoned
- 1997-06-24 CZ CZ984382A patent/CZ438298A3/cs unknown
- 1997-06-24 WO PCT/FR1997/001116 patent/WO1998001540A1/fr not_active Ceased
- 1997-06-24 SK SK1814-98A patent/SK181498A3/sk unknown
- 1997-06-24 IL IL12762097A patent/IL127620A0/xx unknown
- 1997-06-24 US US09/202,314 patent/US6410273B1/en not_active Expired - Fee Related
- 1997-07-03 ZA ZA9705959A patent/ZA975959B/xx unknown
1998
- 1998-12-29 NO NO986177A patent/NO986177L/no not_active Application Discontinuation
2001
- 2001-12-28 US US10/037,488 patent/US20020187527A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1998001540A1 (fr)	1998-01-15
JP2000514293A (ja)	2000-10-31
ZA975959B (en)	1998-01-30
KR20000022488A (ko)	2000-04-25
AU722909B2 (en)	2000-08-17
NO986177L (no)	1999-02-15
US6410273B1 (en)	2002-06-25
IL127620A0 (en)	1999-10-28
US20020187527A1 (en)	2002-12-12
CZ438298A3 (cs)	1999-04-14
FR2750704A1 (fr)	1998-01-09
CA2258792A1 (fr)	1998-01-15
AU3447597A (en)	1998-02-02
FR2750704B1 (fr)	1998-09-25
EP0914418A1 (fr)	1999-05-12
BR9710173A (pt)	1999-08-10
NO986177D0 (no)	1998-12-29

Publication	Publication Date	Title
SK181498A3 (en)	1999-07-12	Method for producing therapeutic dna, application of plasmid dna for producing a pharmaceutical composition
Mayrhofer et al.	2009	Use of minicircle plasmids for gene therapy
JP4756014B2 (ja)	2011-08-24	条件複製起点をもつ環状ｄｎａ分子、それらの製造方法、及び、遺伝子治療におけるそれらの使用
Mairhofer et al.	2008	Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA
JPH11500618A (ja)	1999-01-19	Ｄｎａ分子、その製造及び遺伝子治療における使用
FI120046B (fi)	2009-06-15	Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
CN112154208A (zh)	2020-12-29	产生改进的病毒和非病毒纳米质粒载体
EP1272625A2 (fr)	2003-01-08	PLASMIDES A CpG REDUITS ET VECTEURS VIRAUX
CN115768487A (zh)	2023-03-07	用于面肩肱型肌营养不良症的crispr抑制
Tan et al.	2002	Overcoming the inflammatory toxicity of cationic gene vectors
Schakowski et al.	2007	Minimal size MIDGE vectors improve transgene expression in vivo
MX2007003214A (es)	2007-10-11	Formulaciones liquidas estables de adn plasmidico.
JP4451842B2 (ja)	2010-04-14	遺伝子治療に用いるための製品
US20170096679A1 (en)	2017-04-06	Eukaryotic expression vectors resistant to transgene silencing
US6323003B1 (en)	2001-11-27	Compositions and methods for activating genes of interest
US9816077B2 (en)	2017-11-14	Use of integrase for targeted gene expression
MXPA98010328A (en)	1999-07-06	Terapeut dna production procedure
Tolmachov et al.	2005	Minimized, CpG‐Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy
Bigey et al.	2003	Optimization of plasmid backbone for gene expression in mammalian cells